Suntrust Banks’s Ligand Pharmaceuticals LGND Stock Holding History

Suntrust Banks’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,584	Closed	-$203K	–	1336
2019 Q1	$203K	Buy	+2,584	New	+$196K	﹤0.01%	1228
2018 Q2	–	Sell	-3,594	Closed	-$370K	–	1337
2018 Q1	$370K	Buy	3,594 +239	+7%	+$23.6K	﹤0.01%	983
2017 Q4	$287K	Sell	3,355 -872	-21%	-$75.6K	﹤0.01%	1054
2017 Q3	$359K	Sell	4,227 -229	-5%	-$18.1K	﹤0.01%	984
2017 Q2	$338K	Buy	4,456 +192	+5%	+$13.4K	﹤0.01%	1000
2017 Q1	$282K	Sell	4,264 -4,338	-50%	-$285K	﹤0.01%	1052
2016 Q4	$545K	Buy	8,602 +124	+1%	+$7.83K	﹤0.01%	963
2016 Q3	$539K	Sell	8,478 -244	-3%	-$17.9K	﹤0.01%	936
2016 Q2	$648K	Buy	8,722 +218	+3%	+$16.2K	﹤0.01%	854
2016 Q1	$567K	Buy	8,504 +3,573	+72%	+$217K	﹤0.01%	888
2015 Q4	$332K	Buy	+4,931	New	+$304K	﹤0.01%	1087
2014 Q2	–	Sell	-32,151	Closed	-$1.35M	–	1560
2014 Q1	$1.35M	Buy	+32,151	New	+$1.34M	0.01%	822

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Suntrust Banks's LGND Position: Q2 2019 in Review

Suntrust Banks sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 2,584 shares — an estimated $203K sold.

Suntrust Banks first reported a position in LGND in Q1 2014 and held it in 12 quarters. The position peaked at $1.35M in Q1 2014. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Suntrust Banks reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Suntrust Banks sold 2,584 Ligand Pharmaceuticals shares in Q2 2019, an estimated $203K.
Suntrust Banks first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Suntrust Banks's Ligand Pharmaceuticals position peaked at $1.35M in Q1 2014.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Suntrust Banks's 13F filing for Q2 2019, filed 6 Aug 2019.